ABT Stock Analysis: Buy, Sell, or Hold?
ABT - Abbott Laboratories
$92.11
-1.82 (-1.94%)
▼
5d:
-3.68%
30d:
+3.3%
90d:
-8.17%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 16, 2026
1d
Smart Money Accumulation
None View Scanner →
Strength: 6.3/10
Get Alerted When ABT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABT trading at deep discount. Market pricing in -4.6% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ABT trading at deep discount. Market pricing in -4.6% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$150.22
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$93.27
1.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABT is currently trading at $92.11, which is considered fair relative to its 30-day fair value range of $89.13 to $94.03. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.2) compared to its historical average (17.5). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ABT is in a strong downtrend. The price is currently testing key support at $90.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $116.40 (+26.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABT is in a strong downtrend. The price is currently testing key support at $90.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $116.40 (+26.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$89.13 -
$94.03
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.4% below Wall St target ($116.40)
Trading Range Analysis
30-Day Trading Range
$89.13 -
$94.03
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$90.61
Resistance Level
$98.14
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.21
Wall Street Target
$116.40
(+26.4%)
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
-19.7%
Profit Margin
13.9%
Valuation Discount vs History
-4.6% cheaper
PE vs Historical
15.2 vs 17.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.6%
(market-implied from PE analysis)
1-Year Target
$87.87
(-5%)
2-Year Target
$83.83
(-9%)
3-Year Target
$79.97
(-13%)
3-Yr Target (if PE normalizes)
(PE: 15→18)
$92.02
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 10.5%)
$177.77
(+93%)
Base:
(SPY PE: 15.2, Growth: 10.5%)
$124.14
(+35%)
Bear:
(PE: 12.9, Growth: 10.5%)
$105.52
(+15%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 26.31 | Current EPS (TTM): $3.57
Bull Case
$175.28
(+90%)
Analyst growth 69.6%, PE expands to 28.9
Base Case
$159.34
(+73%)
Market implied 69.6%, PE stable at 26.3
Bear Case
$63.87
(-31%)
Severe decline -20.0%, PE contracts to 22.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.2 to 17.5
Stabilization Target:
$105.98
(+15.1%)
PE Expansion Potential:
+15.1%
Share & Embed Analysis
Last updated: July 14, 2026 4:27 AM ET
Data refreshes hourly during market hours. Next update: 5:27 AM
Data refreshes hourly during market hours. Next update: 5:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABT showing a specific setup today?
Insider Activity (6 Months)
7
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
Laura Friedman
SELL
2026-03-24
Ro Khanna
BUY
2026-03-23
Featured in Portfolios
ABT is a key holding in these high-performance investment strategies.
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 67 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 57 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 62 BUY |
Advanced ABT Option Strategies
Professional options setups generated by AI based on today's ABT price and gamma walls.
